ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

NCI’s Richard Kaplan named associate director, National Cancer Research Network of UK.

January 2, 2004

Finasteride Does Not Affect Quality of Life, Says Study

September 28, 2012

As FDA Weighs its Options on Morcellation, Debate Erupts Over Harvard Device Study

November 21, 2014

DCCR Receives 59 Community Hospital Oncology Program Proposals, Only here From Rural Areas

September 21, 1979

New Therapeutic Modalities In Testing For Patients With Carcinoid Syndrome

November 28, 2003

FDA Grants Orphan Designation To E7777 in T-Cell Lymphoma

August 30, 2013